{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:21:46Z","timestamp":1790533306871,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T00:00:00Z","timestamp":1666569600000},"content-version":"vor","delay-in-days":84,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology in Vitro"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.tiv.2022.105389","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T11:41:58Z","timestamp":1652874118000},"page":"105389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Study of the metabolic stability profiles of perampanel, rufinamide and stiripentol and prediction of drug interactions using HepaRG cells as an in vitro human model"],"prefix":"10.1016","volume":"82","author":[{"given":"Sara","family":"Meirinho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcio","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Fortuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tiv.2022.105389_bb0005","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1517\/17425255.2012.685159","article-title":"The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human","volume":"8","author":"Andersson","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.tiv.2022.105389_bb0010","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1124\/dmd.109.030197","article-title":"Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells","volume":"38","author":"Anth\u00e9rieu","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tiv.2022.105389_bb0015","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.tiv.2012.05.008","article-title":"Optimization of the HepaRG cell model for drug metabolism and toxicity studies","volume":"26","author":"Anth\u00e9rieu","year":"2012","journal-title":"Toxicol. Vitr."},{"key":"10.1016\/j.tiv.2022.105389_bb0020","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s13318-018-0533-3","article-title":"Advanced in vitro HepaRG culture systems for xenobiotic metabolism and toxicity characterization","volume":"44","author":"Ashraf","year":"2019","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.tiv.2022.105389_bb0025","first-page":"453","article-title":"Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development","volume":"58","author":"Baranczewski","year":"2006","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.tiv.2022.105389_bb0030","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1124\/dmd.117.077883","article-title":"Elucidation of the impact of P-glycoprotein and breast cancer resistance protein on the brain distribution of catechol-O-methyltransferase inhibitors","volume":"45","author":"Bicker","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tiv.2022.105389_bb0035","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1177\/1060028019856008","article-title":"Stiripentol: a novel antiseizure medication for the management of Dravet syndrome","volume":"53","author":"Buck","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.tiv.2022.105389_bb0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.14581\/jer.11008","article-title":"New and emerging treatments for epilepsy: review of clinical studies of lacosamide, eslicarbazepine acetate, ezogabine, rufinamide, perampanel, and electrical stimulation therapy","volume":"1","author":"Chung","year":"2011","journal-title":"J. Epilepsy Res."},{"key":"10.1016\/j.tiv.2022.105389_bb0045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/17425255.2019.1560420","article-title":"Pharmacokinetic and pharmacodynamic considerations for the clinical efficacy of perampanel in focal onset seizures","volume":"15","author":"De Biase","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.tiv.2022.105389_bb0055","series-title":"Guideline on bioanalytical method validation","first-page":"1","author":"European Medicines Agency","year":"2011"},{"key":"10.1016\/j.tiv.2022.105389_bb0075","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.tiv.2014.08.004","article-title":"Toxicology in vitro HepaRG cell line as an in vitro model for screening drug \u2013 drug interactions mediated by metabolic induction: amiodarone used as a model substance","volume":"28","author":"Ferreira","year":"2014","journal-title":"Toxicol. Vitr."},{"key":"10.1016\/j.tiv.2022.105389_bb0065","series-title":"Stiripentol (Diacomit). Summary of product characteristics","first-page":"1","author":"European Medicines Agency","year":"2021"},{"key":"10.1016\/j.tiv.2022.105389_bb0060","series-title":"Rufinamide (Inovelon). Summary of product characteristics","first-page":"1","author":"European Medicines Agency","year":"2021"},{"key":"10.1016\/j.tiv.2022.105389_bb0080","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10337-016-3063-7","article-title":"HPLC\u2013DAD method for the quantification of carbamazepine, oxcarbazepine and their active metabolites in HepaRG cell culture samples","volume":"79","author":"Ferreira","year":"2016","journal-title":"Chromatographia"},{"key":"10.1016\/j.tiv.2022.105389_bb0100","article-title":"Guidance for industry In vitro metabolism and transporter mediated drug-drug interaction studies","author":"Food And Drug Administration","year":"2017"},{"key":"10.1016\/j.tiv.2022.105389_bb0070","series-title":"Guidance for Industry Bioanalytical Method Validation","first-page":"1","author":"Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.tiv.2022.105389_bb0050","article-title":"Drug development and drug interactions: table of substrates, inhibitors and inducers","author":"Food and Drug Administration","year":"2020"},{"key":"10.1016\/j.tiv.2022.105389_bb0085","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10565-011-9208-4","article-title":"Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins","volume":"28","author":"Gerets","year":"2012","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.tiv.2022.105389_bb0090","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2174\/1389200043335414","article-title":"Human hepatocytes in primary culture: the choice to investigate drug metabolism in man","volume":"5","author":"Gomez-Lechon","year":"2004","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.tiv.2022.105389_bb0095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cbi.2006.12.003","article-title":"The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics","volume":"168","author":"Guillouzo","year":"2007","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.tiv.2022.105389_bb0105","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2174\/1389200218666170316093301","article-title":"Drug metabolism in preclinical drug development: a survey of the discovery process, toxicology, and computational tools","volume":"18","author":"Issa","year":"2017","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.tiv.2022.105389_bb0110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1124\/dmd.107.017418","article-title":"HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans","volume":"36","author":"Kanebratt","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tiv.2022.105389_bb0115","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1124\/dmd.107.020016","article-title":"Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies","volume":"36","author":"Kanebratt","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tiv.2022.105389_bb0120","first-page":"119","article-title":"Drug interactions involving the new second- and third- generation antiepileptic drugs","volume":"10","author":"Landmark","year":"2010","journal-title":"Expert Rev."},{"key":"10.1016\/j.tiv.2022.105389_bb0125","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1528-1157.1984.tb03448.x","article-title":"Michaelis-Menten kinetics of stiripentol in normal humans","volume":"25","author":"Levy","year":"1984","journal-title":"Epilepsia"},{"key":"10.1016\/j.tiv.2022.105389_bb0130","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ejpb.2014.06.012","article-title":"Cyclosporin A affects the bioavailability of ginkgolic acids via inhibition of P-gp and BCRP","volume":"88","author":"Li","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.tiv.2022.105389_bb0135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.vascn.2010.04.013","article-title":"HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro","volume":"63","author":"L\u00fcbberstedt","year":"2011","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.tiv.2022.105389_bb0140","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jchromb.2019.06.021","article-title":"Novel bioanalytical method for the quantification of rufinamide in mouse plasma and tissues using HPLC-UV: a tool to support pharmacokinetic studies","volume":"1124","author":"Meirinho","year":"2019","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.tiv.2022.105389_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/jssc.202000656","article-title":"Salting-out assisted liquid-liquid extraction method optimized by design of experiments for the simultaneous HPLC analysis of perampanel and stiripentol in mouse matrices","author":"Meirinho","year":"2020","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.tiv.2022.105389_bb0150","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jpha.2020.11.005","article-title":"Liquid chromatographic methods for determination of the new antiepileptic drugs stiripentol, retigabine, rufinamide and perampanel: a comprehensive and critical review","volume":"11","author":"Meirinho","year":"2021","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.tiv.2022.105389_bb0155","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40263-017-0432-1","article-title":"Stiripentol in the management of epilepsy","volume":"31","author":"Nickels","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.tiv.2022.105389_bb0160","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2174\/1872312812666180119114013","article-title":"Cytochrome P450 1A2 messenger RNA is a more reliable marker than cytochrome P450 1A2 activity, phenacetin O-deethylation, for assessment of induction potential of drug-metabolizing enzymes using HepaRG cells","volume":"12","author":"Ogasawara","year":"2018","journal-title":"Drug Metab. Lett."},{"key":"10.1016\/j.tiv.2022.105389_bb0165","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40262-013-0087-0","article-title":"Drug interactions with the newer antiepileptic drugs (AEDs) - part 1: pharmacokinetic and pharmacodynamic interactions between AEDs","volume":"52","author":"Patsalos","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.tiv.2022.105389_bb0170","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40262-013-0088-z","article-title":"Drug interactions with the newer antiepileptic drugs (AEDs) - part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders","volume":"52","author":"Patsalos","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.tiv.2022.105389_bb0175","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/FTD.0000000000000274","article-title":"Perampanel serum concentrations in adults with epilepsy: effect of dose, age, sex, and concomitant anti-epileptic drugs","volume":"38","author":"Patsalos","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.tiv.2022.105389_bb0180","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.tiv.2022.105389_bb0185","series-title":"Rufinamide: Clinical pharmacokinetics and concentration \u2013 response relationships","first-page":"1123","volume":"49","author":"Perucca","year":"2008"},{"key":"10.1016\/j.tiv.2022.105389_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/prp2.161","article-title":"Applicability of second-generation upcyte \u00ae human hepatocytes for use in CYP inhibition and induction studies","volume":"3","author":"Ramachandran","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.tiv.2022.105389_bb0195","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/DDDT.S154388","article-title":"Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines","volume":"12","author":"Reimers","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.tiv.2022.105389_bb0200","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ane.12100","article-title":"Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist","volume":"127","author":"Rogawski","year":"2013","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.tiv.2022.105389_bb0205","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cbi.2006.07.001","article-title":"Structure, function and regulation of carboxylesterases","volume":"162","author":"Satoh","year":"2006","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.tiv.2022.105389_bb0210","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1517\/17425255.2015.1061504","article-title":"Perampanel for epilepsy with partial-onset seizures: a pharmacokinetic and pharmacodynamic evaluation","volume":"11","author":"Schulze-Bonhage","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.tiv.2022.105389_bb0215","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3109\/00498254.2015.1118774","article-title":"Evaluation of cytochrome P450 inductions by anti-epileptic drug oxcarbazepine, 10-hydroxyoxcarbazepine, and carbamazepine using human hepatocytes and HepaRG cells","volume":"46","author":"Sugiyama","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1016\/j.tiv.2022.105389_bb0220","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1517\/17425255.2016.1145657","article-title":"Pharmacological considerations in the use of stiripentol for the treatment of epilepsy","volume":"12","author":"Verrotti","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.tiv.2022.105389_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/s19102245","article-title":"Cytochrome P450 1A1\/2, 2B6 and 3A4 HepaRG cell-based biosensors to monitor hepatocyte differentiation, drug metabolism and toxicity","volume":"19","author":"Vlach","year":"2019","journal-title":"Sensors (Switzerland)"},{"key":"10.1016\/j.tiv.2022.105389_bb0230","doi-asserted-by":"crossref","first-page":"29295","DOI":"10.1074\/jbc.M400580200","article-title":"Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin","volume":"279","author":"Wang","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tiv.2022.105389_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2016.00461","article-title":"Opportunities and challenges for drug development: public-private partnerships, adaptive designs and big data","volume":"7","author":"Yildirim","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tiv.2022.105389_bb0240","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.apsb.2018.04.003","article-title":"Drug metabolism in drug discovery and development","volume":"8","author":"Zhang","year":"2018","journal-title":"Acta Pharm. Sin. B"}],"container-title":["Toxicology in Vitro"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233322000868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233322000868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:42:42Z","timestamp":1760136162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887233322000868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":48,"alternative-id":["S0887233322000868"],"URL":"https:\/\/doi.org\/10.1016\/j.tiv.2022.105389","relation":{},"ISSN":["0887-2333"],"issn-type":[{"value":"0887-2333","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study of the metabolic stability profiles of perampanel, rufinamide and stiripentol and prediction of drug interactions using HepaRG cells as an in vitro human model","name":"articletitle","label":"Article Title"},{"value":"Toxicology in Vitro","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tiv.2022.105389","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"105389"}}